Mangoceuticals, Inc. Financing Cash Flow
Mangoceuticals, Inc. (MGRX) reported Financing Cash Flow of $316.94 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.08M, a 85.61% increase year-over-year.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.62M, a 116.21% increase year-over-year.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $1.28M, a 35.58% decline year-over-year.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $2.29M, a 754.21% increase year-over-year.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $7.27M, a 76.12% increase from fiscal 2024.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $4.13M, a 41.50% decline from fiscal 2023.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $7.06M, a 244.26% increase from fiscal 2022.
- Mangoceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $2.05M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $316.94K 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $3.71M derived: sum of 2 quarters · filed 2026-04-01 | $4.99M derived: sum of 3 quarters · filed 2026-08-13 | $7.27M 10-K · filed 2026-04-01 | |
| 2025-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.90M derived: sum of 2 quarters · filed 2026-08-13 | $5.19M 10-Q · filed 2025-11-14 | $6.31M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.57M 10-Q · filed 2026-08-13 | $4.69M derived: sum of 3 quarters · filed 2026-08-13 | $5.44M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $2.29M 10-Q · filed 2026-05-19 | $3.41M derived: sum of 2 quarters · filed 2026-05-19 | $4.16M derived: sum of 3 quarters · filed 2026-05-19 | $6.15M derived: sum of 4 quarters · filed 2026-05-19 | |
| 2024-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $1.87M derived: sum of 2 quarters · filed 2026-04-01 | $3.86M derived: sum of 3 quarters · filed 2026-04-01 | $4.13M 10-K · filed 2026-04-01 | |
| 2024-09-30 | $750.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-11-14 | $2.74M derived: sum of 2 quarters · filed 2025-11-14 | $3.01M 10-Q · filed 2025-11-14 | $4.21M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $1.99M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2025-11-14 | $2.26M 10-Q/A · filed 2025-11-14 | $3.46M derived: sum of 3 quarters · filed 2025-11-14 | $3.46M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-03-31 | $267.50K 10-Q · filed 2025-05-15 | $1.47M derived: sum of 2 quarters · filed 2025-05-15 | $1.47M derived: sum of 3 quarters · filed 2025-05-15 | $2.32M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.20M derived: sum of 2 quarters · filed 2025-03-20 | $2.06M derived: sum of 3 quarters · filed 2025-03-20 | $7.06M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $857.04K derived: sum of 2 quarters · filed 2024-11-14 | $5.86M 10-Q · filed 2024-11-14 | $6.36M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $857.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.86M 10-Q · filed 2024-08-14 | $6.36M derived: sum of 3 quarters · filed 2024-08-14 | $7.83M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $5.00M 10-Q · filed 2024-05-15 | $4.92M 10-Q · filed 2023-05-10 | $5.50M derived: sum of 2 quarters · filed 2024-05-15 | $6.97M derived: sum of 3 quarters · filed 2024-05-15 | $7.00M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $499.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.98M derived: sum of 2 quarters · filed 2024-04-01 | $2.00M derived: sum of 3 quarters · filed 2024-04-01 | $2.05M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | $1.50M derived: sum of 2 quarters · filed 2023-10-27 | $1.55M 10-Q · filed 2023-10-27 | ||
| 2022-06-30 | $24.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $74.93K 10-Q · filed 2023-07-28 | |||
| 2022-03-31 | $50.00K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |